TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes from baseline in area under the curve of serum glucose, C-peptide, and insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in fasting serum glucose and insulin as measured by HOMA-IR2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and severity of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Latency of Antidromic median sensory nerve action potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of Antidromic median sensory nerve action potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gut Microbiome and Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Multi-omic Expression of Genes, Proteins, and Metabolites in the Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical and Emotional Health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Management of pyrexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change In Patient Assessment of Constipation Symptoms (PAC-SYM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean continuous change in Sleep Condition Indicator Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of women with SCI score >16
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in EGG parameters (WLST, GMA, Predominant frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mortality in hospital or palliative discharge
Endpoint domain: Mortality/survival
Primary endpoint: Mortality at 6 weeks after diagnosis of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Dermatological Tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Skin Barrier Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Numeric Rating Scale (NRS) mean change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of efficacy of endoscopic gastrointestinal anastomoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of complications during endoscopic gastrointestinal anastomoses
Endpoint domain: Adverse events/effects
Primary endpoint: Quantity of tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort level using CL Discomfort Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Contraceptive safety
Endpoint domain: Adverse events/effects
Primary endpoint: Increased cardiac biomarkers (Troponin I and BNP/NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in functional capacity assessed by estimated VO2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle-brachial pulse wave velocity (baPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of Trauma Informed Care Plans
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endoscopist detection of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immunity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of past 28-day binge drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of past 28-day binge eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Young Adult Alcohol Consequences Questionnaire (B-YAACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-injury behavior assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L-beta frequency peak power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the total score of the Pittsburgh sleep quality index (PSQI) at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Cessation rate of Western medicine hypnotics at Month 6
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Employment Status
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Income
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Housing Stability
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Savings
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Self Reported HIV Risk Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Compliance With Recommended Biomedical Prevention or Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improving IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity grade of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Experience of Service
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fluorescein break up time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration (CMax) for CBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration (CMax) for CBD-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration (CMax) for THC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration (CMax) for THC-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for CBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for CBD-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Feasibility, Acceptability, Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Yale-Brown obsessive compulsive scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women initiating PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: peak Standard Uptake Value (SUVpeak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean Standard Uptake Value (SUVmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum Standard Uptake Value (SUVmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elastography Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myokine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in inflammatory marker IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in % number of days drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Alcohol Concentration (BAC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in no. of drinks consumed following stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alcohol craving following stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Madrid Sonographic Enthesitis Index (MASEI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DACTylitis glObal Sonographic (DACTOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent of 95th percentile BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tri-ponderal mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AHSP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of PT/OT session
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nucleus Accumbens Brain Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gambling Choice Behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Hematological indicators (hematocrit, hemoglobin and cell count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ventilatory thresholds and maximum oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PROMIS Depression - Short Form 8b
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Anxiety - Short Form 7a
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse Events (AE) and serious AE associated with Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Version 3.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Reasoning Readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-directed Learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Chest Tube Care Management Knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year ocular salvage rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of acute GVH
Endpoint domain: Adverse events/effects
Primary endpoint: Capabilities of Upper Extremity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of skeletal-related events (SREs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of intraventricular hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Subject-rated drug effects of abuse liability
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited injection-site adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serotype-specific opsonophagocytic activity geometric mean titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in the Hamilton Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale changes for pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment emergent adverse events of special interest (TEAESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Upper Extremity Remote Fugl-Meyer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Migraine Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HOOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sustained wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in corneal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Four Influenza Vaccine Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Titers to Vaccine O-serotype Antigens 29 days After Administration of ExPEC9V on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Titers to Vaccine O-serotype Antigens 29 days After Administration of ExPEC9V on Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of serious complications
Endpoint domain: Adverse events/effects
Primary endpoint: pacing lead dislodgement
Endpoint domain: Adverse events/effects
Primary endpoint: pocket hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: pericardial effusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of systemic infection associated with intracerebral hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cerebritis, meningitis, ventriculitis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of HIV Viral Load Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Cost Effectiveness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mPR post-SABR with or without pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+ TRM in baseline biopsy and post-nephrectomy specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TCF-1 + tumour infiltrating lymphocytes (TILs) in baseline biopsy and post-nephrectomy specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Vitamin D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Childhood Autism Rating Scale, Second edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum urate (uric acid) level < 6 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Analog Scale for Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Moderate & Severe Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scapular Static Positioning Assessment: Upper distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scapular Static Positioning Assessment: Lower distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 30-day acute care revisits for COPD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Next intervention-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Degree of radiation-induced oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in activity limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in high-density lipoprotein (HDL) Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Change in low-density lipoprotein (LDL) Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Change in Total Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Proportion of Participants who are Insulin Independent with Absence of Severe Hypoglycemic Events (SHEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Neuropsychological Assessment Battery Naming Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knowledge and attitudes regarding bloodstream infection prevention
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge and attitudes regarding urinary tract infection control precautions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Characterization of immune cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sexual Orientation Documentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gender Identity Documentation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinics with Staff/Provider Training Completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reaching task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of post-COVID-19 POTS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in photophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual photosensitivity thresholds (VPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke-related disability rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Detection of pathogenic or likely pathogenic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with a PreP prescription within one month of intervention completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with a positive blood spot test for PrEP 6 months following the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Minutes of Moderate Physical Activity Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Minutes of Vigorous Physical Activity Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Number of Food Intake Behaviors Met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Level of urinary metabolomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of Level of urinary proteomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adoption of LARC
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adoption of modern contraceptive method
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference of Testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in Clinical Biochemistry of CK level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of Muscle damage - blood level of myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of CardioFlux MCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived effectiveness of the reading device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of the dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: The rate of complete response within two cycles of treatment with CN201
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS Biodistribution of [89Zr]Zr-DFO-BIIB080
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of SSEPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hand Dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flashes Scale Specific to Menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale-Brown Obsessive Compulsive Scale - II (YBOCS-II)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Leisure time physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Position of the tibial canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Position of the femoral canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time of negative conversion of SARS-CoV-2 nucleic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes